Adaptive TCR Raises $5.8M to Invest in Clinical Applications

The latest investment will be used to grow the company's immune system sequencing service, immunoSeq, and "invest in clinical applications in the oncology, autoimmune, and vaccine fields," CEO Chad Robins said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.